PMID- 29375123
OWN - NLM
STAT- MEDLINE
DCOM- 20190913
LR  - 20200306
IS  - 2042-0226 (Electronic)
IS  - 1672-7681 (Print)
IS  - 1672-7681 (Linking)
VI  - 15
IP  - 4
DP  - 2018 Apr
TI  - The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally?
PG  - 335-345
LID - 10.1038/cmi.2017.135 [doi]
AB  - Macrophages are one of the most abundant leukocyte populations infiltrating tumor 
      tissues and can exhibit both tumoricidal and tumor-promoting activities. In 1989, 
      we reported the purification of monocyte chemoattractant protein-1 (MCP-1) from 
      culture supernatants of mitogen-activated peripheral blood mononuclear cells and 
      tumor cells. MCP-1 is a potent monocyte-attracting chemokine, identical to the 
      previously described lymphocyte-derived chemotactic factor or tumor-derived 
      chemotactic factor, and greatly contributes to the recruitment of blood monocytes 
      into sites of inflammatory responses and tumors. Because in vitro-cultured tumor 
      cells often produce significant amounts of MCP-1, tumor cells are considered to 
      be the main source of MCP-1. However, various non-tumor cells in the tumor stroma 
      also produce MCP-1 in response to stimuli. Studies performed in vitro and in vivo 
      have provided evidence that MCP-1 production in tumors is a consequence of 
      complex interactions between tumor cells and non-tumor cells and that both tumor 
      cells and non-tumor cells contribute to the production of MCP-1. Although MCP-1 
      production was once considered to be a part of host defense against tumors, it is 
      now believed to regulate the vicious cycle between tumor cells and macrophages 
      that promotes the progression of tumors.
FAU - Yoshimura, Teizo
AU  - Yoshimura T
AD  - Department of Pathology and Experimental Medicine, Graduate School of Medicine, 
      Dentistry and Pharmaceutical Sciences, Okayama University, 700-8558, Kita-ku, 
      Okayama, Japan. yoshimut@okayama-u.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180129
PL  - China
TA  - Cell Mol Immunol
JT  - Cellular & molecular immunology
JID - 101242872
RN  - 0 (Chemokine CCL2)
SB  - IM
MH  - Animals
MH  - Chemokine CCL2/genetics/*metabolism
MH  - Disease Models, Animal
MH  - Humans
MH  - Neoplasm Transplantation
MH  - Neoplasms/*metabolism
MH  - Transcription, Genetic
MH  - Tumor Microenvironment
PMC - PMC6052833
OTO - NOTNLM
OT  - chemokines
OT  - cytokines
OT  - inflammation
OT  - macrophages
OT  - tumor microenvironment
COIS- The author declares no conflict of interest.
EDAT- 2018/01/30 06:00
MHDA- 2019/09/14 06:00
PMCR- 2019/04/01
CRDT- 2018/01/30 06:00
PHST- 2017/07/30 00:00 [received]
PHST- 2017/10/18 00:00 [accepted]
PHST- 2017/10/13 00:00 [revised]
PHST- 2018/01/30 06:00 [pubmed]
PHST- 2019/09/14 06:00 [medline]
PHST- 2018/01/30 06:00 [entrez]
PHST- 2019/04/01 00:00 [pmc-release]
AID - 10.1038/cmi.2017.135 [pii]
AID - 80 [pii]
AID - 10.1038/cmi.2017.135 [doi]
PST - ppublish
SO  - Cell Mol Immunol. 2018 Apr;15(4):335-345. doi: 10.1038/cmi.2017.135. Epub 2018 
      Jan 29.